STK32A Activators
The class of STK32A activators is primarily composed of compounds that function by indirectly enhancing STK32A through their effects on other proteins and signaling pathways. For instance, Resveratrol activates SIRT1, which could influence STK32A via the SIRT1/p53 pathway. Other notable members of this class include Forskolin, an activator of adenylate cyclase, which can increase cAMP levels and subsequently activate Protein Kinase A (PKA). PKA, in turn, may enhance STK32A activity by phosphorylation.
Additional compounds that fall under this class include inhibitors of various protein kinases. Staurosporine, a potent protein kinase C (PKC) inhibitor, and H89, a potent PKA inhibitor, may enhance STK32A by reducing PKC- and PKA-mediated cellular signaling events, respectively, that could negatively regulate STK32A. Similarly, Y-27632, a selective inhibitor of ROCK (Rho-associated, coiled-coil containing protein kinase), can indirectly enhance STK32A by reducing ROCK-mediated cellular signaling events. Genistein, an inhibitor of protein tyrosine kinases, could indirectly enhance STK32A by reducing tyrosine kinase-mediated cellular signaling events. Lastly, PP2, an inhibitor of Src family tyrosine kinases, could indirectly enhance STK32A by reducing Src-mediated cellular signaling events. The collective action of these compounds on various pathways and proteins can lead to the enhancement of STK32A's functional activity, highlighting their importance in the modulation of this protein.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol is a natural phenol that activates SIRT1, a protein that deacetylates numerous substrates including p53. STK32A, as a serine/threonine kinase, could be influenced by the SIRT1/p53 pathway, enhancing its activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is an activator of adenylate cyclase, which increases cAMP levels. Increased cAMP can activate Protein Kinase A (PKA), which may enhance STK32A activity by phosphorylation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a potent protein kinase C (PKC) inhibitor, may enhance STK32A by reducing PKC-mediated cellular signaling events that could negatively regulate the activity of STK32A. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of mammalian target of rapamycin (mTOR), a protein that may negatively regulate STK32A. By inhibiting mTOR, it could indirectly enhance STK32A. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H89 is a potent PKA inhibitor. By inhibiting PKA, it could enhance STK32A by reducing PKA-mediated cellular signaling events that could negatively regulate STK32A. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated, coiled-coil containing protein kinase). By inhibiting ROCK, it could indirectly enhance STK32A by reducing ROCK-mediated cellular signaling events that could negatively regulate STK32A. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a phytoestrogen, is an inhibitor of protein tyrosine kinases. By inhibiting these kinases, it may indirectly enhance STK32A by reducing tyrosine kinase-mediated cellular signaling events. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. By inhibiting Src kinase, it may indirectly enhance STK32A by reducing Src-mediated cellular signaling events that could negatively regulate STK32A. | ||||||